Therapeutics News and Research

RSS

Researchers devise new approach to improve current T-cell therapy methods

T-cell therapy, a form of immunotherapy that uses a patient's own immune cells to attack their cancer, has been making waves recently. The "living" therapy involves engineering the patient's T cells in the laboratory to carry new proteins that guide the immune cells directly to tumor cells, allowing the engineered T cells to attack and kill the cancer.

23 Feb 2016

Researchers Pinpoint Potential Enzyme For T-Cell Leukemia Treatment

For the first time, researchers at Boston University have shown that T-cell leukemia cells use a particular cycle, called the TCA or Kreb cycle, to support their growth and survival.

23 Feb 2016

Pitt experts lead gene therapy clinical trial in Parkinson's disease patients

Experts at the University of Pittsburgh School of Medicine are leading the second arm of a clinical trial using gene therapy to relieve the symptoms of tremor and mobility impairment in patients with Parkinson's disease.

23 Feb 2016

UA College of Pharmacy assistant professor developing dry powder inhalers to treat pulmonary diseases

Heidi M. Mansour, PhD, assistant professor in the University of Arizona College of Pharmacy, is working to develop advanced dry powder inhalers to treat and prevent pulmonary diseases.

23 Feb 2016

Two Johns Hopkins scientists named among 105 winners of Presidential Early Career Awards

Namandje Bumpus, Ph.D., and Jordan Green, Ph.D., of the Johns Hopkins University School of Medicine are among 105 winners of Presidential Early Career Awards for Scientists and Engineers, which were announced by the White House on Feb. 18.

23 Feb 2016

Regulus reports net loss of $7.2 million for fourth quarter 2015

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and full-year ended December 31, 2015 and provided a summary of recent corporate highlights.

23 Feb 2016

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study.

22 Feb 2016

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).

22 Feb 2016

Calgary researchers develop new class of nanomedicines to treat autoimmune diseases

A new study from the University of Calgary could change the way researchers understand and treat autoimmune diseases such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis.

22 Feb 2016

Researchers identify new group of powerful Ebola-fighting antibodies

A research team that included scientists from The Scripps Research Institute has identified a new group of powerful antibodies to fight Ebola virus.

22 Feb 2016

Penn researchers develop new mathematical model to estimate mutation rates in the human genome

It turns out that the type, how frequent, and where new mutations occur in the human genome depends on which DNA building blocks are nearby, found researchers from the Perelman School of Medicine at the University of Pennsylvania in an advanced online study published this week in Nature Genetics.

22 Feb 2016

New visiongain report on Zika virus

What can be expected as the Zika outbreak progresses? Which areas are going to be the most affected? This visiongain report discusses the future direction of the Zika virus outbreak and the implications of its spread. It also discussed the infectious disease diagnostics market and the global human vaccines market, both of which are forecast to 2026.

22 Feb 2016

TSRI's Courtney Miller to receive Presidential Early Career Award for Scientists and Engineers

Courtney Miller, associate professor on the Florida campus of The Scripps Research Institute, has been selected to receive a Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the United States government on young professionals at the outset of their independent research careers.

19 Feb 2016

Parvus' novel therapeutic approach employing nanomedicines published in Nature

Parvus Therapeutics today announced the publication in Nature of a seminal paper describing the discovery and applications of a novel therapeutic approach employing nanomedicines, referred to as "Navacims"TM, to reprogram white blood cells to become regulatory cells capable of blunting autoimmune responses and restoring the equilibrium of the immune system.

19 Feb 2016

New treatment protects mice from MERS infection

In a new study, University of Maryland School of Medicine researchers have had promising results with a new treatment for Middle East Respiratory Syndrome (MERS). The study, published today in the journal Science Translational Medicine, found a new treatment that protected mice from MERS infection.

18 Feb 2016

FDA issues new guidance to reduce risk of Zika blood transmission

As a safety measure against the emerging Zika virus outbreak, today the U.S. Food and Drug Administration issued a new guidance recommending the deferral of individuals from donating blood if they have been to areas with active Zika virus transmission, potentially have been exposed to the virus, or have had a confirmed Zika virus infection.

18 Feb 2016

Corvidia Therapeutics secures $26 million in Series A financing

Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.

18 Feb 2016

Small peptide TAxI holds promise for carrying biologic drugs into spinal cord

A small peptide dubbed TAxI is living up to its name. Recent studies show it to be an effective vehicle for shuttling functional proteins, such as active enzymes, into the spinal cord after a muscle injection.

17 Feb 2016

Apogenix awarded €3 million grant to develop immuno-oncology candidate APG101 as personalized therapy

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it has received funding approval in the amount of €3 million from the German Federal Ministry of Education and Research for the so-called CancerMark project.

16 Feb 2016

Study could pave way for new treatment strategies for PKU

Phenylketonuria, also known as PKU, is the most common inherited disease affecting amino acid metabolism. Children are tested for PKU at birth, and babies diagnosed with the disease must adhere to a highly restricted diet to prevent permanent intellectual impairment.

16 Feb 2016

Therapeutics News and Research

Researchers devise new approach to improve current T-cell therapy methods

Researchers Pinpoint Potential Enzyme For T-Cell Leukemia Treatment

Pitt experts lead gene therapy clinical trial in Parkinson's disease patients

UA College of Pharmacy assistant professor developing dry powder inhalers to treat pulmonary diseases

Two Johns Hopkins scientists named among 105 winners of Presidential Early Career Awards

Regulus reports net loss of $7.2 million for fourth quarter 2015

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Calgary researchers develop new class of nanomedicines to treat autoimmune diseases

Researchers identify new group of powerful Ebola-fighting antibodies

Penn researchers develop new mathematical model to estimate mutation rates in the human genome

New visiongain report on Zika virus

TSRI's Courtney Miller to receive Presidential Early Career Award for Scientists and Engineers

Parvus' novel therapeutic approach employing nanomedicines published in Nature

New treatment protects mice from MERS infection

FDA issues new guidance to reduce risk of Zika blood transmission

Corvidia Therapeutics secures $26 million in Series A financing

Small peptide TAxI holds promise for carrying biologic drugs into spinal cord

Apogenix awarded €3 million grant to develop immuno-oncology candidate APG101 as personalized therapy

Study could pave way for new treatment strategies for PKU

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News